ABSTRACT
We have argued that the EU-US conflict over biotechnology products is an opportunity to study the global governance of a new technology, for several reasons. EU-US interactions, and their regulatory frameworks and standards, have profound implications at the global level. In addition, although the EU and the US often approach the rest of the world with a transatlantic consensus, in this case they found themselves increasingly in conflict. As their dispute intensified, and their regulatory approaches diverged, they began to present competing regulatory models to other countries around the world. This raised the political stakes for transatlantic regulatory differences and for strategies to mediate the conflicts.
